Influences of interleukin 1B and interleukin 1RN polymorphisms on the development of non-ulcer dyspepsia, duodenal ulcer and gastric cancer in Turkish population
Abstract number: 1134_02_56
Kocazeybek B., Erzin Y., Koksal V., Erdamar S., Altun S., Dobrucali A.
IL-1B and IL-1RN gene polymorphisms (which encode interleukin 1B and interleukin-1 receptor antagonist, respectively) have been associated with development of gastric atrophy and with increased risk of gastric carcinoma. The aim of this study was to determine the influences of host IL-1B -31TC, IL-1B -511CT and IL-1B RN gene polymorphisms on the development of various gastroduodenal pathologies in 93 Helicobacter pylori (Hp) positive Turkish patients [(30 with non-ulcer dyspepsia (NUD), 30 with duodenal ulcer (DU) and 33 with gastric cancer (GC)].
Genomic DNA was extracted from Hp positive paraffin embedded gastric biopsy samples of 30 NUD, 30 DU and 33 GC patients. IL-1B and IL-1B RN gene polymorphisms were analysed by polymerase chain reaction-restriction fragment length polymorphism. These polymorphic sites include promoter regions of IL-1B at positions-511 (CT transition) and -31 (TC transition), and IL-1 RN variable tandem repeats (intron2 VNTR).
There were no statistically significant difference among three clinical outcomes in the frequencies of IL-1B -511CT + TT and IL-1B -31 TC + CC genotypes (as called proinflamatory genotypes) (p = 0.161 and p = 0.077, respectively). The prevalence of the proinflamatory IL-1B RN 1/2 + 2/2 alleles in GC group was higher than that in NUD and DU groups. The frequencies of IL-1B RN 1/2 + 2/2 alleles were 20.0% (6/30) in NUD; 31.0% (9/30) in DU; and 57.6% (19/33) in GC group, showing statistically significant differences (p = 0.006).
There were no statistically significant difference among three clinical outcomes in the frequencies of IL-1B -511CT + TT and IL-1B -31 TC + CC genotypes, whereas proinflamatory IL-1B RN *2 allele (1/2 + 2/2) was associated with gastric cancer in Turkey.
|Session name:||XXIst ISTH Congress|
|Back to top|